Cara Therapeutics Stock News

Within the last quarter, Cara Therapeutics (NASDAQ:CARA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 0 0 0 La

U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday. The Dow traded down 0.77% to 33,172.39 while the NASDAQ fell 0.72% to 11,591.36. The S&P 500

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 20 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.03% to 33,420.92 while the NASDAQ rose

No matter what the Fed chief has to say this week, the market has one idea stuck in its brain right now, and it's all wrong, says our call of the day from volatility expert Harley Bassman.

Gainers Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) rose 64.6% to $0.6912 in pre-market trading after the company provided an update on its regulatory strategy for AD04. Adial will pursue paths toward

Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close

Cara Therapeutics, Inc. (NASDAQ: CARA) posted downbeat Q4 results. Cara Therapeutics posted a Q4 loss of $0.56 per share, versus market expectations of $0.32 per share. The company’s quarterly sales

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Cara Therapeutics, Inc. (NASDAQ: CARA) shares dropped 30.6% to $6.94

Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.

The market closed mixed, but these two companies gave investors some bad news.

Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company’s share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million incl

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves

Markets finished mixed on Monday. Calavo suffered from the downward price impact of supply gluts of avocados from Mexico.

Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?